Ocular Manifestation of Non-Parenchymal Neuro-Behçet Syndrome

Background

Behçetʼs disease (BD) has been first described by Hippocrates, while it has been brought back to attention by Hulusi Behçet. Its classical triad includes recurrent, usually painful oral and genital ulcers and uveitis [1].

• References

• 1 Behçet H. Über rezidivierende, aphthose durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157
• 2 Kokturk A. Clinical and pathological manifestations with differential diagnosis in Behçetʼs Disease. Patholog Res Int 2012; 2012: 690390
• 3 Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76
• 4 Siva A, Saip S. The spectrum of nervous system involvement in Behçetʼs syndrome and its differential diagnosis. J Neurol 2009; 256: 513-529
• 5 Krist D, Schönherr U, Wenkel H. [Adamantiadis-Behçet syndrome: fluorescein angiography and choroid ischemia]. Klin Monbl Augenheilkd 2000; 216: 45-50
• 6 Keino H, Okada AA, Watanabe T et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçetʼs disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245-1250
• 7 Hatemi G, Silman A, Bang D et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-1662
• 8 Fresko I, Yazici H. Treatment strategies for Behçetʼs disease. Expert Opin Pharmacother 2008; 9: 3211-3219
• 9 Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçetʼs disease: an update. Curr Opin Rheumatol 2011; 23: 24-31
• 10 Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012; 130: 592-598